Format
Items per page

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

bortezomib

A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. [from MeSH]

MedGen UID:
222095
Concept ID:
C1176309
Organic Chemical; Pharmacologic Substance
2.

Lymphoma

Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as . -Swollen, painless lymph nodes in the neck, armpits or groin. -Unexplained weight loss . -Fever . -Soaking night sweats . -Coughing, trouble breathing or chest pain . -Weakness and tiredness that don't go away . -Pain, swelling or a feeling of fullness in the abdomen . Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses substances that attack cancer cells without harming normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute.  [from MedlinePlus]

MedGen UID:
44223
Concept ID:
C0024299
Neoplastic Process
3.

Mantle cell lymphoma

Mantle cell lymphoma is a rare form of malignant non-Hodgkin lymphoma (see this term) affecting B lymphocytes in the lymph nodes in a region called the ``mantle zone''. [from ORDO]

MedGen UID:
798955
Concept ID:
CN205223
Finding
4.

Lymphoma

A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [from HPO]

MedGen UID:
505322
Concept ID:
CN002422
Finding
5.

Mantle cell lymphoma

A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1). [from MeSH]

MedGen UID:
87278
Concept ID:
C0334634
Neoplastic Process
6.

Zinc

An element with atomic symbol Zn, atomic number 30, and atomic weight 65.39. [from NCI]

MedGen UID:
22752
Concept ID:
C0043481
Biologically Active Substance; Element, Ion, or Isotope; Pharmacologic Substance
7.

disease-free survival

MedGen UID:
776920
Concept ID:
CN186048
Finding
8.

Hereditary leiomyomatosis and renal cell cancer

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is characterized by cutaneous leiomyomata (multiple or single in 76% of affected individuals), uterine leiomyomata (fibroids), and/or a single renal tumor. Cutaneous leiomyomata appear as skin-colored to light brown papules or nodules distributed over the trunk and extremities, and occasionally on the face, and appear at a mean age of 25 years, increasing in size and number with age. Uterine leiomyomata are present in almost all females with HLRCC and tend to be numerous and large; age at diagnosis ranges from 18 to 52 years, with most women experiencing irregular or heavy menstruation and pelvic pain. Renal tumors causing hematuria, lower back pain, and a palpable mass are usually unilateral, solitary, and aggressive and range from type 2 papillary to tubulo-papillary to collecting-duct carcinomas. They occur in about 10%-16% of individuals with HLRCC; the median age of detection is 44 years. [from GeneReviews]

MedGen UID:
353771
Concept ID:
C1708350
Neoplastic Process
9.

Proteasome inhibitor

A drug that blocks the action of proteasomes. A proteasome is a large protein complex that helps destroy other cellular proteins when they are no longer needed. Proteasome inhibitors are being studied in the treatment of cancer. [from NCI_NCI-GLOSS]

MedGen UID:
252947
Concept ID:
C1443643
Pharmacologic Substance
10.

Neoplasm

A malignant tumor at the original site of growth. [from NCI]

MedGen UID:
227011
Concept ID:
C1306459
Neoplastic Process
11.

Proliferation

MedGen UID:
137720
Concept ID:
C0334094
Pathologic Function
12.

Mediator brand of benfluorex hydrochloride

An agent that acts as a link between parties, objects, or actions. [from NCI]

MedGen UID:
93010
Concept ID:
C0127400
Organic Chemical; Pharmacologic Substance
13.

B-cell lymphoma

A type of lymphoma that originates in B-cells. [from HPO]

MedGen UID:
86953
Concept ID:
C0079731
Neoplastic Process
14.

Distal

Localized away from the central point of the body. [from HPO]

MedGen UID:
64375
Concept ID:
C0205108
Spatial Concept
15.

Proximal

Localized close to the central point of the body. [from HPO]

MedGen UID:
64374
Concept ID:
C0205107
Spatial Concept
16.

Lymphosarcoma

An obsolete term for a malignant tumor of lymphatic tissue. [from NCI_NCI-GLOSS]

MedGen UID:
811370
Concept ID:
C3714542
Neoplastic Process
17.

LDP-341

MedGen UID:
253835
Concept ID:
C1135131
Organic Chemical; Pharmacologic Substance
18.

Velcade

MedGen UID:
225113
Concept ID:
C1174739
Organic Chemical; Pharmacologic Substance
19.

Lymphoma, Lymphocytic, Intermediate

MedGen UID:
199774
Concept ID:
C0751958
Disease or Syndrome
20.

Lymphatism

MedGen UID:
141817
Concept ID:
C0524631
Disease or Syndrome
Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center